دورية أكاديمية
أعرض في EDS

Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer.

التفاصيل البيبلوغرافية
العنوان: Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer.
المؤلفون: Lorentzen EH; Department of Surgery, Brigham and Women's Hospital, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA. Electronic address: ehhersh@bwh.harvard.edu., Minami CA; Department of Surgery, Brigham and Women's Hospital, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.
المصدر: Clinical breast cancer [Clin Breast Cancer] 2024 Jun; Vol. 24 (4), pp. 319-327. Date of Electronic Publication: 2024 Feb 13.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : [New York] : Elsevier
Original Publication: Dallas, Tex. : Cancer Information Group
مواضيع طبية MeSH: Breast Neoplasms*/therapy , Breast Neoplasms*/pathology , Geriatric Assessment* , Overtreatment*, Humans ; Female ; Aged ; Neoplasm Staging ; Aged, 80 and over ; Frailty ; Age Factors
مستخلص: Advances in the treatment of older women with early-stage breast cancer, particularly opportunities for de-escalation of therapy, have afforded patients and providers opportunity to individualize care. As the majority of women ≥65 have estrogen receptor-positive, HER2-negative disease, locoregional therapy (surgery and/or radiation) may be tailored based on a patient's physiologic age to avoid either over- or undertreatment. To determine who would derive benefit from more or less intensive therapy, an accurate assessment of an older patient's physiologic age and incorporation of patient-specific values are paramount. While there now exist well-validated geriatric assessment tools whose use is encouraged by the American Society of Clinical Oncology when considering systemic therapy, these instruments have not been widely integrated into the locoregional breast cancer care model. This review aims to highlight the importance of assessing frailty and the concepts of and over- and undertreatment, in the context of trial data supporting opportunities for safe deescalation of locoregional therapy, when treating older women with early-stage breast cancer.
Competing Interests: Disclosure The authors have stated that they have no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
References: JAMA Surg. 2023 Jun 1;158(6):664-666. (PMID: 36920410)
BJU Int. 2007 Dec;100(6):1254-8. (PMID: 17979925)
J Clin Oncol. 2013 Jul 1;31(19):2382-7. (PMID: 23690420)
J Surg Res. 2020 Dec;256:577-583. (PMID: 32805580)
JAMA. 2006 Feb 15;295(7):801-8. (PMID: 16478903)
Br J Surg. 2015 Apr;102(5):525-33; discussion 533. (PMID: 25708660)
Ann Surg Oncol. 2020 Sep;27(9):3426-3433. (PMID: 32215758)
J Oncol Pract. 2018 Jul;14(7):442-446. (PMID: 29932846)
N Engl J Med. 2023 Feb 16;388(7):585-594. (PMID: 36791159)
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):870-3. (PMID: 15708268)
J Clin Oncol. 2006 Jan 20;24(3):337-44. (PMID: 16344321)
J Clin Oncol. 2024 Feb 1;42(4):390-398. (PMID: 38060195)
Br J Surg. 1991 May;78(5):591-4. (PMID: 2059815)
J Am Coll Surg. 2022 Apr 1;234(4):450-464. (PMID: 35290264)
JAMA Surg. 2015 Jan;150(1):9-16. (PMID: 25408966)
Ann Surg Oncol. 2016 Oct;23(10):3371-8. (PMID: 27364507)
Breast Cancer Res Treat. 2023 Aug;201(1):89-104. (PMID: 37326766)
Psychooncology. 2008 Apr;17(4):410-6. (PMID: 17847124)
JAMA. 2023 Aug 22;330(8):693-694. (PMID: 37540519)
J Natl Compr Canc Netw. 2021 Sep 20;19(9):1006-1019. (PMID: 34551388)
PLoS One. 2014 Dec 11;9(12):e115060. (PMID: 25503576)
Eur J Cancer. 2003 Feb;39(3):309-16. (PMID: 12565982)
Breast Cancer Res Treat. 2017 Jul;164(1):107-117. (PMID: 28364214)
Eur J Cancer. 2021 Jan;142:48-62. (PMID: 33220653)
N Engl J Med. 2021 Dec 16;385(25):2336-2347. (PMID: 34914339)
JAMA Surg. 2020 Jan 1;155(1):e194620. (PMID: 31721994)
J Geriatr Oncol. 2015 Jan;6(1):46-51. (PMID: 25267539)
Breast Cancer Res Treat. 2011 Apr;126(2):529-37. (PMID: 20803066)
JAMA Surg. 2018 Dec 1;153(12):1090-1096. (PMID: 30167636)
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):334-40. (PMID: 17363187)
Curr Geriatr Rep. 2014 Sep;3(3):182-189. (PMID: 25587518)
N Engl J Med. 2002 Aug 22;347(8):567-75. (PMID: 12192016)
J Am Geriatr Soc. 2018 Aug;66(8):1455-1458. (PMID: 29727469)
Ann Surg Oncol. 2017 Jan;24(1):100-107. (PMID: 27654110)
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. (PMID: 29523670)
Breast. 2014 Dec;23(6):793-8. (PMID: 25212636)
Breast J. 2020 May;26(5):976-980. (PMID: 32057177)
J Natl Cancer Inst. 2016 Sep 27;109(1):. (PMID: 27678203)
Curr Oncol. 2022 Dec 27;30(1):392-400. (PMID: 36661681)
N Engl J Med. 2015 Nov 19;373(21):2005-14. (PMID: 26412349)
J Clin Oncol. 2010 Jan 20;28(3):380-6. (PMID: 20008637)
Eur J Surg Oncol. 1994 Jun;20(3):207-14. (PMID: 8181594)
J Natl Cancer Inst. 2022 Mar 8;114(3):391-399. (PMID: 34747484)
Cancer. 2015 Jan 15;121(2):188-93. (PMID: 25488523)
N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498)
J Clin Oncol. 2011 Apr 1;29(10):1290-6. (PMID: 21357782)
Breast Cancer Res Treat. 2019 Dec;178(3):637-645. (PMID: 31451977)
Eur J Cancer. 2012 Apr;48(6):805-12. (PMID: 21741826)
J Clin Oncol. 2002 Oct 15;20(20):4141-9. (PMID: 12377957)
Psychooncology. 2019 Jul;28(7):1367-1380. (PMID: 30838697)
J Gen Intern Med. 2009 Oct;24(10):1115-22. (PMID: 19649678)
Expert Rev Anticancer Ther. 2022 May;22(5):535-548. (PMID: 35588396)
Crit Care Clin. 2021 Jan;37(1):151-174. (PMID: 33190767)
JAMA Oncol. 2020 Feb 1;6(2):196-204. (PMID: 31697365)
Ann Oncol. 2003 Mar;14(3):414-20. (PMID: 12598347)
J Clin Oncol. 2020 Aug 1;38(22):2558-2569. (PMID: 32250717)
Surg Oncol. 2017 Dec;26(4):359-367. (PMID: 29113653)
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. (PMID: 37733364)
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004272. (PMID: 16437480)
J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):980-987. (PMID: 29244057)
Br J Surg. 2020 Oct;107(11):1468-1479. (PMID: 32488911)
Ann Surg. 2007 May;245(5):665-71. (PMID: 17457156)
J Am Coll Surg. 2015 Dec;221(6):1083-92. (PMID: 26422746)
J Clin Oncol. 2023 Sep 10;41(26):4293-4312. (PMID: 37459573)
Ann Surg Oncol. 2022 Apr 6;:. (PMID: 35385998)
J Clin Oncol. 2023 May 1;41(13):2331-2336. (PMID: 36538740)
J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):724-30. (PMID: 18693227)
Ann Surg. 2012 Dec;256(6):920-4. (PMID: 23154393)
PLoS One. 2020 May 20;15(5):e0229518. (PMID: 32434215)
Eur J Surg Oncol. 2014 Jul;40(7):805-12. (PMID: 24768443)
Crit Rev Oncol Hematol. 2003 Mar;45(3):313-25. (PMID: 12633842)
Breast J. 2021 Jun;27(6):509-513. (PMID: 33650221)
معلومات مُعتمدة: R03 AG073986 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: Frailty; Geriatric assessment; Life expectancy; Overtreatment; Undertreatment
تواريخ الأحداث: Date Created: 20240309 Date Completed: 20240609 Latest Revision: 20240723
رمز التحديث: 20240723
مُعرف محوري في PubMed: PMC11261391
DOI: 10.1016/j.clbc.2024.02.004
PMID: 38461117
قاعدة البيانات: MEDLINE
الوصف
تدمد:1938-0666
DOI:10.1016/j.clbc.2024.02.004